First patient cells collected in XNK’s preclinical bladder cancer study
XNK Therapeutics AB (“XNK”) today announced that the first patient has donated cells in the recently initiated preclinical evaluation of the autologous NK cell product XNK03 in locally advanced or metastatic urothelial cancer. The study is performed in collaboration with Anders Ullén’s research group at the Karolinska University Hospital, Stockholm, Sweden.This is the company’s first solid tumor indication and complements the ongoing Phase II clinical study in multiple myeloma (MM) and the preclinical proof-of-concept study in acute myeloid leukemia (AML) using patient samples from The